Frank Y Wang

发表

Lance G. Laing, B. Cunningham, Peter Y. Li, 2004, Journal of biomolecular screening.

Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC

T. Clackson, R. Anjum, V. Rivera, 2012 .

Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened

K. Kotkow, L. Rubin, F. D. de Sauvage, 2011, Clinical Cancer Research.

Bacterial volatiles promote growth in Arabidopsis

J. Greer, H. Wichterle, Y. Rao, 2003 .

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

T. Clackson, R. Anjum, V. Rivera, 2016, Clinical Cancer Research.

Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)

T. Clackson, L. Berk, V. Rivera, 2008 .

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

T. Clackson, B. Druker, A. Corbin, 2007 .

Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066)

T. Clackson, R. Anjum, V. Rivera, 2010 .

Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)

T. Clackson, R. Anjum, V. Rivera, 2009 .

Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.

T. Clackson, R. Anjum, V. Rivera, 2013 .

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

J. Fletcher, T. Clackson, M. Heinrich, 2014, Clinical Cancer Research.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

T. Clackson, B. Druker, A. Corbin, 2009, Cancer cell.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2010, Journal of medicinal chemistry.

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

T. Clackson, R. Anjum, V. Rivera, 2016, Journal of medicinal chemistry.

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

T. Clackson, B. Druker, J. Tyner, 2011, Molecular Cancer Therapeutics.

Preclinical Development Potent Activity of Ponatinib ( AP 24534 ) in Models of FLT 3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

T. Clackson, B. Druker, J. Tyner, 2011 .

Identification of a small molecule inhibitor of the hedgehog signaling pathway: Effects on basal cell carcinoma-like lesions

H. Wichterle, L. Rubin, J. Williams, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists

H. Wichterle, L. Rubin, D. Bumcrot, 2002, Journal of biology.

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

T. Clackson, R. Anjum, V. Rivera, 2011, Chemical biology & drug design.

Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

T. Clackson, V. Rivera, D. Clapham, 2011, Molecular Cancer Therapeutics.

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

T. Clackson, L. Berk, V. Rivera, 2011, Molecular Cancer Therapeutics.

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

T. Clackson, V. Rivera, W. Shakespeare, 2012, Molecular Cancer Therapeutics.

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models

T. Clackson, V. Rivera, Frank Y Wang, 2012, International journal of oncology.

Preclinical Development Ridaforolimus ( AP 23573 ; MK-8669 ) , a Potent mTOR Inhibitor , Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

T. Clackson, L. Berk, V. Rivera, 2011 .

9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.

G. Daley, T. Clackson, M. Azam, 2009, Journal of medicinal chemistry.

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

T. Clackson, B. Druker, A. Corbin, 2006 .

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib

J. Pritchard, H. Edgren, Tzu-Hsiu Chen, 2018, Oncotarget.

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

T. Clackson, V. Rivera, M. Wongchenko, 2013, Cancer Chemotherapy and Pharmacology.

Preclinical Development Ponatinib ( AP 24534 ) , aMultitargeted Pan-FGFR Inhibitorwith Activity in Multiple FGFR-Ampli fi ed or Mutated Cancer Models

T. Clackson, V. Rivera, W. Shakespeare, 2012 .

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2011, Bioorganic & medicinal chemistry letters.

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.

T. Clackson, T. Sawyer, W. Shakespeare, 2008, Bioorganic & medicinal chemistry letters.